Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PortugalBack to Portugal

Clinical trials in Senhora Da Hora – page 48

679 clinical trials in Senhora Da Hora, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Senhora Da Hora at a glance
679
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

679 trials in Senhora Da Hora

Open in trial search

Chronic inflammatory demyelinating polyradiculoneuropathy

Not recruiting

Study on the Effects and Safety of Riliprubart for Patients with Chronic Inflammatory Demyelinating Polyneuropathy Unresponsive to Usual Treatments

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Pulmonary arterial hypertension

Not recruiting

Study on Long-term Safety of Seralutinib for Patients with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Seralutinib
  • Sponsor:GB002 Inc.

Pulmonary hypertension

Not recruiting

Study on the Long-term Safety and Efficacy of Ralinepag for Patients with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Ralinepag
  • Sponsor:United Therapeutics Corp.

Asthma

Not recruiting

Study Comparing Depemokimab, Mepolizumab, and Benralizumab for Adults and Adolescents with Severe Eosinophilic Asthma

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Type 2 diabetes mellitus

Not recruiting

Study on the Effectiveness and Safety of Oral Semaglutide Compared to Placebo in Children and Adolescents with Type 2 Diabetes Using Metformin or Basal Insulin

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Neoplasm

Not recruiting

Study of MDNA11 Alone or with Pembrolizumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:MDNA11
  • Sponsor:Medicenna Therapeutics Inc.

Cystic fibrosis

Not recruiting

Study on Long-term Safety of VX-121, Tezacaftor, and Deutivacaftor in Patients with Cystic Fibrosis

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tezacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Myasthenia gravis

Not recruiting

Study on the Effects of Iptacopan in Patients with Generalized Myasthenia Gravis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Paroxysmal nocturnal haemoglobinuria

Not recruiting

Study on the Effectiveness and Safety of Crovalimab vs. Eculizumab for Adults and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Treated with Complement Inhibitors

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Crovalimab
  • Sponsor:F. Hoffmann-La Roche AG

Non-small cell lung cancer

Not recruiting

Study of Pembrolizumab for Patients with Early Stage Non-Small Cell Lung Cancer After Surgery and Standard Therapy

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Portugal

The busiest research cities in the country

All 47 cities in Portugal

Clinical research in Senhora Da Hora

What the registry says about research in the country

01 Neurology & Mental Health

Innovative research focusing on Alzheimer's disease and associated conditions, including studies on psychosis treatment and cognitive decline prevention. Multiple trials exploring migraine prevention with novel therapeutic approaches.

  • Alzheimer's Disease Management
  • Migraine Prevention
  • Multiple Sclerosis Treatment

Studies are evaluating both symptomatic relief and disease modification strategies.

02 Oncology

Comprehensive research in breast cancer treatments, particularly focusing on HR+/HER2- variants and innovative combination therapies. Advanced studies in non-small cell lung cancer exploring new treatment paradigms.

  • Breast Cancer Therapeutics
  • Lung Cancer Treatment
  • Head and Neck Cancer

Trials emphasize targeted therapies and immunotherapy approaches.

03 Respiratory Medicine

Groundbreaking research in severe asthma management and chronic rhinosinusitis. Studies evaluating new treatments for COPD with focus on long-term safety and efficacy.

  • Asthma Management
  • COPD Treatment
  • Rhinosinusitis Therapy

Emphasis on innovative inhaler combinations and targeted biological treatments.

Back to PortugalAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.